Clinical Trials Logo

BCC clinical trials

View clinical trials related to BCC.

Filter by:
  • None
  • Page 1

NCT ID: NCT06279143 Recruiting - Skin Diseases Clinical Trials

The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes

dOCT-pBCC
Start date: April 4, 2024
Phase:
Study type: Observational

The purpose is to investigate the diagnostic value (sensitivity and specificity) of dermal-Optical Coherence Tomography (D-OCT, VivoSight Dx), in patients with clinically suspected BCC lesions inside the periocular region and compare these results to previous reports using D-OCT in diagnosing lesions outside the periocular area. The Hypotheses: - The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is comparable to previous reports on BCC lesions outside the periocular region when the standard D-OCT probe is used. - The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is increased when the customised D-OCT probe is used. - The sensitivity and specificity of D-OCT in diagnosing periocular BCC is comparable to punch biopsy when both standard and the customised D-OCT probes are used. - D-OCT with the 10 and 20-millimeter standoff is capable of subtyping periocular BCC. - The inter-observer variation in diagnosing and sub-typing periocular BCC decreases with increasing experience in the scanning procedure. - The number of scans to correctly interpret D-OCT decreases with increasing experience in the scanning procedure. - Delineation of periocular BCC tumour extension is possible using both D-OCT probes

NCT ID: NCT06150144 Recruiting - Clinical trials for Basal Cell Carcinoma

The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

Start date: May 25, 2023
Phase: Phase 3
Study type: Interventional

The investigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

NCT ID: NCT05859074 Recruiting - Melanoma Clinical Trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Start date: May 4, 2023
Phase: Phase 1
Study type: Interventional

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

NCT ID: NCT04918381 Completed - Clinical trials for BCC - Basal Cell Carcinoma

CellFX Treat & Resect Low-Risk BCC Feasibility Study

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.

NCT ID: NCT04552990 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.

NCT ID: NCT02007317 Completed - BCC Clinical Trials

Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.